Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
暂无分享,去创建一个
Yasuhiko Tsukada | J. Saito | Y. Tanino | H. Ohtani | K. Sugino | Yuichi Waragai | T. Nikaido | A. Fukuhara | R. Kanno | Y. Inokoshi | J. Morimoto | T. Azuma | E. Sando | M. Nakayama | Yasuhito Suzuki | N. Watanabe | R. Togawa | H. Minemura | K. Tanigawa | W. Abe | M. Kamimoto | H. Tomita | Tatsuho Kobayashi | Mitsuru Waragai | Sugihiro Hamaguchi | Y. Shibata | N. Kanzaki | Riko Sato | Hiroyuki Saito | H. Kume | T. Ishida | Ryuki Yamada | T. Onuma | Kiyoshi Saito | H. Sakuma | Y. Nakamura | H. Okamoto | Ken Iseki | Toshiyuki Kambe | Keiji Sakamoto | Y. Sato | Kenya Kanazawa | Shinsaku Maeda | Mami Rikimaru | Mikako Saito | Takaya Kawamata | Shuzo Suzuki | Hideko Aoki | Akira Takama | Taku Iizuka | T. Kamiyama | Masahiko Sato | Tomoyoshi Lee
[1] Y. Kurahashi,et al. Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron’s outbreak , 2022, PloS one.
[2] A. Cathcart,et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.
[3] Y. Liu,et al. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta , 2022, Journal of Travel Medicine.
[4] Shinji Watanabe,et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 , 2022, The New England journal of medicine.
[5] Y. Liu,et al. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta , 2022, Journal of travel medicine.
[6] Kwang Su Kim,et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 , 2022, bioRxiv.
[7] K. Rosenke,et al. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model , 2022, bioRxiv.
[8] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[9] A. Harries,et al. Faculty Opinions recommendation of Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. , 2022, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[10] D. Fremont,et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.
[11] M. Wass,et al. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates , 2022, Cell Research.
[12] H. Jäck,et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.
[13] J. Butterton,et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.
[14] E. Callaway. Heavily mutated Omicron variant puts scientists on alert , 2021, Nature.
[15] K. Shiraki,et al. Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection , 2021, Journal of clinical medicine.
[16] Mei Peng,et al. Role of Hypertension on the Severity of COVID-19: A Review , 2021, Journal of cardiovascular pharmacology.
[17] T. Kawahara,et al. Using Propensity Scores for Causal Inference: Pitfalls and Tips , 2021, Journal of epidemiology.
[18] R. Pranata,et al. Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression , 2021, Clinical medicine insights. Endocrinology and diabetes.
[19] John D. Davis,et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[20] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[21] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[22] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[23] P. Austin,et al. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.